Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability, safety and activity of IDN5243 in the treatment of low back pain
2015-001742-29Phase 2Completed
- Sponsor
- Indena
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IDN 5243 in lumbodynia (LBP), sponsored by Indena. Primary endpoint: Systemic safety and local tolerability of IDN5243 over 5 days. Started Feb 2018; status: completed.
02
Drugs
IDN 5243
03
Conditions
lumbodynia (LBP)
Beyond the preview
Go deeper on 2015-001742-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001742-29.